APOBEC3A drives tumor evolution and intratumoral heterogeneity in pdac

The Klinikum Rechts der Isar der TU München (TUM) has received a $398,750 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program to investigate the role of APOBEC3A in pancreatic cancer from 2023-2026. Through this award, TUM will conduct biomedical research to better understand the impact of APOBEC3A on tumor evolution and intratumoral heterogeneity in pancreatic ductal adenocarcinoma (PDAC). In addition to this prime award, TUM has participated as a subawardee on several federal grants related to diabetes, cancer, atherosclerosis, multiple sclerosis, and other disease research. As a subawardee, TUM provides collaborative research support such as data, samples, patient recruitment, and analysis to prime grantees like the University of California and the Trustees of Columbia University.